1 00:00:05,275 --> 00:00:07,325 - This is the Becker's Healthcare Podcast, created 2 00:00:07,325 --> 00:00:08,445 by the team of Becker's Healthcare, 3 00:00:08,605 --> 00:00:10,365 a multimedia company devoted to the people 4 00:00:10,385 --> 00:00:11,645 who power us healthcare. 5 00:00:11,955 --> 00:00:14,765 Four new 15 minute episodes are released daily containing 6 00:00:14,965 --> 00:00:16,725 industry news analysis and thought leadership. 7 00:00:16,725 --> 00:00:19,605 From powerful healthcare decision makers Support our show 8 00:00:19,745 --> 00:00:22,565 by leaving it a five star rating and review on Apple Podcast 9 00:00:22,785 --> 00:00:24,045 or other platforms you use. 10 00:00:24,195 --> 00:00:26,045 It's a chance to tell us what you like about the show 11 00:00:26,065 --> 00:00:27,285 and act on your feedback. 12 00:00:27,285 --> 00:00:29,245 Thanks for listening. Now here's the episode. 13 00:00:30,555 --> 00:00:32,805 - This is Chris Doso with the Becker's Healthcare Podcast. 14 00:00:33,265 --> 00:00:34,445 I'm thrilled today to be joined by Dr. 15 00:00:34,535 --> 00:00:35,885 Boris pch, president 16 00:00:35,885 --> 00:00:38,685 and CEO of the Karmanos Cancer Institute in Detroit, 17 00:00:40,225 --> 00:00:41,885 an internationally round cancer researcher. 18 00:00:41,995 --> 00:00:43,125 He's also chair of the Department 19 00:00:43,125 --> 00:00:45,405 of Oncology at Wayne State University School of Medicine. 20 00:00:45,865 --> 00:00:47,765 Dr. Pass, thank you so much for joining us today. 21 00:00:48,935 --> 00:00:51,045 - Thank you for the opportunity to speak with you. 22 00:00:52,155 --> 00:00:55,005 - Certainly, uh, understandably you've had an extensive 23 00:00:55,105 --> 00:00:56,205 career, but Dr. 24 00:00:56,205 --> 00:00:57,645 Pass, would you mind telling us a little 25 00:00:57,765 --> 00:00:58,805 bit more about your background? 26 00:00:59,615 --> 00:01:03,285 - Happy to. Yes. I grew up in the French speaking part 27 00:01:03,285 --> 00:01:06,005 of Switzerland and, uh, went to medical, 28 00:01:06,005 --> 00:01:09,085 started medical school in, in Switzerland, uh, 29 00:01:09,225 --> 00:01:12,365 and then, um, moved to Sweden, uh, at 30 00:01:12,385 --> 00:01:15,685 to Stockholm more precisely at the Carolines Care Institute 31 00:01:16,055 --> 00:01:19,805 where I received my MD and my PhD degrees. 32 00:01:20,465 --> 00:01:22,565 Um, thereafter I moved to the US 33 00:01:22,625 --> 00:01:25,685 and I was a postdoctoral fellow at, uh, the Brigham 34 00:01:25,685 --> 00:01:27,605 and Women Hospital at Harvard Medical School 35 00:01:27,705 --> 00:01:30,405 for three years prior to moving to New York, 36 00:01:30,415 --> 00:01:34,325 where I trained in internal medicine at Cornell, uh, 37 00:01:34,785 --> 00:01:36,965 and then in, uh, hematology 38 00:01:36,965 --> 00:01:39,685 and oncology at Memorial Sloan Kettering Cancer Center. 39 00:01:40,105 --> 00:01:41,965 That's where I continued my work 40 00:01:42,025 --> 00:01:45,845 and research, um, at the Howard Hugs Medical Institutes 41 00:01:45,905 --> 00:01:46,925 and the lab of Dr. 42 00:01:46,925 --> 00:01:47,925 Joan Maga. 43 00:01:48,065 --> 00:01:51,085 That's where I discovered the first mutation of the type one 44 00:01:51,685 --> 00:01:55,925 TGF beta receptor, which really propelled my academic, 45 00:01:56,185 --> 00:01:57,325 uh, research career. 46 00:01:58,165 --> 00:02:00,725 I then moved to, um, uh, Northwestern 47 00:02:00,855 --> 00:02:03,125 where I started my own lab, 48 00:02:03,425 --> 00:02:04,725 and I was also the founder 49 00:02:04,785 --> 00:02:08,925 of the Northwestern Cancer Genetics Program working on tumor 50 00:02:08,945 --> 00:02:10,525 susceptibility genes. 51 00:02:11,065 --> 00:02:15,245 Um, in 2008, I was offered the position of director 52 00:02:15,245 --> 00:02:18,525 of the division of Hematology oncology at the University 53 00:02:18,525 --> 00:02:19,925 of Alabama in Birmingham. 54 00:02:20,145 --> 00:02:24,925 Um, and, uh, I was there until 2014, um, 55 00:02:25,105 --> 00:02:26,245 and also served there as 56 00:02:26,245 --> 00:02:27,845 Deputy director of the Cancer Center. 57 00:02:28,505 --> 00:02:31,805 In 2014, I became the, uh, director 58 00:02:31,825 --> 00:02:35,285 of the Wake Forest Baptist Comprehensive Cancer Center 59 00:02:35,745 --> 00:02:38,525 and the chair of the Department of Cancer Biology, uh, 60 00:02:38,725 --> 00:02:41,685 position I held until, uh, 2022. 61 00:02:42,185 --> 00:02:46,885 And in 2023, I moved to, um, Karmanos to become the new, uh, 62 00:02:46,915 --> 00:02:49,365 president and CEO as you indicated. 63 00:02:49,625 --> 00:02:53,045 So my background is both, uh, as a physician scientist. 64 00:02:53,185 --> 00:02:56,125 I'm trained as a, an oncologist in hematology 65 00:02:56,225 --> 00:02:57,405 and medical oncology, 66 00:02:58,105 --> 00:03:02,485 and I see mostly patient with gastrointestinal malignancies. 67 00:03:03,105 --> 00:03:05,125 I'm also, uh, the inventor 68 00:03:05,125 --> 00:03:08,565 and developer of a novel technology for the treatment of, 69 00:03:08,665 --> 00:03:11,645 uh, cancer, which recently received FDA approval 70 00:03:11,865 --> 00:03:12,885 for its first indication. 71 00:03:13,505 --> 00:03:15,925 Uh, so I think that sums up my, uh, background. 72 00:03:17,485 --> 00:03:18,675 - Thank you so much, doctor. 73 00:03:20,085 --> 00:03:22,345 I'm glad you mentioned, uh, the device that you mentioned. 74 00:03:22,385 --> 00:03:23,625 I do wanna get to that a little bit later, 75 00:03:24,045 --> 00:03:25,585 but off the top here, 76 00:03:25,665 --> 00:03:27,865 I understand you feel strongly about cancer screening 77 00:03:27,865 --> 00:03:29,505 guidelines, uh, to what do you 78 00:03:29,505 --> 00:03:30,985 or your passion regarding the subject 79 00:03:31,245 --> 00:03:33,385 and how should the healthcare industry adjust course? 80 00:03:34,425 --> 00:03:36,285 - So I think cancer screening is one 81 00:03:36,285 --> 00:03:38,165 of the most successful achievement 82 00:03:38,185 --> 00:03:41,005 of cancer research in the past few decades. 83 00:03:41,745 --> 00:03:46,045 Um, I think, uh, in my area of expertise, colorectal cancer, 84 00:03:46,945 --> 00:03:51,245 the, um, um, the IM implementation of any form of screening, 85 00:03:51,245 --> 00:03:55,925 but preferably colonoscopy decreases the risk of dying from 86 00:03:55,955 --> 00:03:58,565 that deadly disease by about 40%. 87 00:03:59,225 --> 00:04:01,285 And that's, uh, uh, quite dramatic. 88 00:04:01,585 --> 00:04:04,765 And, uh, it is also a disease that is very common. 89 00:04:05,185 --> 00:04:08,285 It is the second most common tumor type in non-smoker 90 00:04:08,285 --> 00:04:09,885 and the third in non-smokers. 91 00:04:10,425 --> 00:04:15,285 Um, so I think I've seen the benefits, the value, 92 00:04:15,905 --> 00:04:19,885 uh, of, uh, screening in multiple instances, 93 00:04:20,345 --> 00:04:23,405 and especially when you're interested in inherited form 94 00:04:23,405 --> 00:04:26,245 of cancer in patient who have a family history 95 00:04:26,265 --> 00:04:29,805 of colorectal cancer screening plays an even a more 96 00:04:29,805 --> 00:04:33,965 important role because you really save lives early on, uh, 97 00:04:34,115 --> 00:04:35,165 just by screening 98 00:04:35,165 --> 00:04:36,965 and removing early polyps 99 00:04:36,995 --> 00:04:39,725 that could develop into deadly cancers. 100 00:04:41,665 --> 00:04:45,315 - Certainly it's beneficial to everyone that this type 101 00:04:45,315 --> 00:04:47,035 of advancement has been made over the course 102 00:04:47,055 --> 00:04:48,195 of, uh, decades. 103 00:04:48,455 --> 00:04:52,555 Uh, what I did want to ask you also in relation to that, um, 104 00:04:52,555 --> 00:04:54,235 what are the keys to reducing racial 105 00:04:54,295 --> 00:04:56,235 and ethnic disparities in cancer treatment, 106 00:04:56,495 --> 00:04:59,275 and how can other hospitals and health systems follow suit? 107 00:05:00,645 --> 00:05:03,025 - So I think this is a very important issue. 108 00:05:03,285 --> 00:05:07,265 The, um, you, you see that, um, um, racial 109 00:05:07,405 --> 00:05:10,545 and ethnic disparities in in the United States are quite 110 00:05:10,985 --> 00:05:11,985 prominent, uh, 111 00:05:12,445 --> 00:05:16,745 and in certain region, the, uh, the rate of screening is, 112 00:05:16,845 --> 00:05:21,505 is very low, uh, which certainly, uh, decreases the, 113 00:05:22,085 --> 00:05:26,345 the ability to impact cancer before it occurs or, 114 00:05:26,345 --> 00:05:29,385 or develop, uh, some example in the Detroit area 115 00:05:29,535 --> 00:05:33,065 with a very low rate of HPV vaccination 116 00:05:33,645 --> 00:05:35,905 and a low rate of HPV vaccination, 117 00:05:35,915 --> 00:05:40,225 especially in ethnic minorities, results in a higher rate 118 00:05:40,525 --> 00:05:44,465 of, uh, cervical cancer, but also of head and neck cancer. 119 00:05:44,965 --> 00:05:49,025 And these two tumors that are easily screened for or, 120 00:05:49,085 --> 00:05:52,825 or treated, uh, it can be prevented with these, um, 121 00:05:53,455 --> 00:05:54,505 with vaccination. 122 00:05:54,565 --> 00:05:57,445 So when you have, you have a very low rate of vaccination 123 00:05:58,105 --> 00:06:00,605 in, uh, younger individual 124 00:06:00,605 --> 00:06:03,765 because this is when, uh, vaccination should occur. 125 00:06:04,265 --> 00:06:07,925 Uh, it's will lead to a higher rate of tumors. 126 00:06:08,425 --> 00:06:10,165 So one of our faculty, Dr. 127 00:06:10,525 --> 00:06:12,565 Ariel Washington, is focusing on 128 00:06:12,565 --> 00:06:17,125 that at Car Cancer Institute on how to impact 129 00:06:17,225 --> 00:06:21,605 or change the, uh, acceptance of, uh, of, 130 00:06:22,145 --> 00:06:24,005 um, HPV vaccination 131 00:06:24,585 --> 00:06:28,445 and has developed strategies to, uh, enhance the rate 132 00:06:28,465 --> 00:06:29,485 of vaccination and 133 00:06:29,485 --> 00:06:34,365 therefore prevent cancer, um, in, uh, large proportion 134 00:06:34,465 --> 00:06:38,085 of the Detroits and Detroit area population. 135 00:06:40,805 --> 00:06:42,825 - Uh, on those, on that note, rather, Dr. 136 00:06:43,015 --> 00:06:45,825 Pash, how does the Karmanos Institute work with its partners 137 00:06:45,825 --> 00:06:47,785 to advance treatments for cancer? 138 00:06:47,885 --> 00:06:50,105 And how would you advise others in your position who want 139 00:06:50,105 --> 00:06:51,785 to achieve similar goals and results? 140 00:06:53,145 --> 00:06:56,885 - So Karmanos has been very successful in expanding the 141 00:06:57,545 --> 00:07:01,205 depths and breadth of its reach within the state of Michigan 142 00:07:01,665 --> 00:07:05,645 and northern Ohio by establishing 16, uh, 143 00:07:05,835 --> 00:07:08,885 different centers that provide patients 144 00:07:09,435 --> 00:07:12,725 screening treatments according to guidelines 145 00:07:12,955 --> 00:07:16,005 that are the same as at the, uh, Maine, uh, 146 00:07:16,295 --> 00:07:18,765 Caros Cancer Institute in downtown Detroit. 147 00:07:19,385 --> 00:07:22,165 So that has allowed patient to have access 148 00:07:22,265 --> 00:07:24,605 to state-of-the-art treatment, uh, 149 00:07:25,105 --> 00:07:28,565 state-of-the-art clinical trial novel technologies, uh, 150 00:07:28,565 --> 00:07:31,445 to treat their cancer close to their home. 151 00:07:31,795 --> 00:07:36,125 Just this morning I was in Roseville, uh, in Macomb County, 152 00:07:36,505 --> 00:07:41,085 uh, to, for the inauguration of the renovated Roseville, uh, 153 00:07:41,315 --> 00:07:44,005 Kaus Cancer Institute, which is very impressive, 154 00:07:44,065 --> 00:07:47,085 and provide state-of-the-art, uh, cancer treatment 155 00:07:47,085 --> 00:07:49,765 for the large, um, McComb County 156 00:07:49,825 --> 00:07:54,765 and Roseville community, which doesn't have, uh, many, many, 157 00:07:54,945 --> 00:07:59,085 uh, options to access, uh, high quality cancer care, uh, 158 00:07:59,155 --> 00:08:01,005 without traveling quite far away. 159 00:08:01,065 --> 00:08:05,645 And the, uh, mayor of Roseville was expressing his, uh, his, 160 00:08:05,945 --> 00:08:07,405 uh, pleasure and, 161 00:08:07,505 --> 00:08:10,725 and, uh, a satisfaction about the fact that 162 00:08:10,745 --> 00:08:12,325 for many elderly patient 163 00:08:12,425 --> 00:08:16,805 or patient with, uh, disability difficulty with transport, 164 00:08:16,805 --> 00:08:20,445 that they now will be able to get, uh, cancer care close 165 00:08:20,445 --> 00:08:23,205 to their home and especially high quality cancer care. 166 00:08:23,905 --> 00:08:28,775 So I think that's a good example of how Carmano is impacting 167 00:08:29,335 --> 00:08:32,935 a large fraction of the Michigan population, uh, 168 00:08:33,295 --> 00:08:36,855 treating more than 14,000, uh, new patients 169 00:08:36,855 --> 00:08:40,855 with cancer per year, more than one third of the entire, uh, 170 00:08:40,855 --> 00:08:43,695 population of patient with cancer in the state of Michigan. 171 00:08:46,025 --> 00:08:47,635 - Certainly efforts like that are, 172 00:08:47,635 --> 00:08:50,435 are very heart heartwarming and worthwhile after. 173 00:08:50,655 --> 00:08:52,675 I'm so glad that analysis has been able 174 00:08:52,675 --> 00:08:53,675 to make those inroads 175 00:08:53,675 --> 00:08:56,845 and certainly access to most kinds 176 00:08:56,845 --> 00:08:58,285 of healthcare has been on the minds 177 00:08:58,285 --> 00:09:00,285 of leaders such as yourself. 178 00:09:00,285 --> 00:09:02,325 So thank you for outlining all of that. 179 00:09:02,425 --> 00:09:04,845 Uh, did I also want to circle back 180 00:09:04,905 --> 00:09:06,845 to the treatment that you mentioned? 181 00:09:07,245 --> 00:09:09,965 I would say before, recently, I had no idea that a spoon 182 00:09:10,635 --> 00:09:13,505 such as it is in this case, could be used 183 00:09:13,625 --> 00:09:16,385 to help treat cancer that is just mind boggling 184 00:09:16,405 --> 00:09:17,585 and wonderfully exciting. 185 00:09:17,845 --> 00:09:19,865 So I wanted to ask you about the bionic 186 00:09:20,165 --> 00:09:21,425 and how it came to be. 187 00:09:21,765 --> 00:09:23,585 In addition to that, what excites you about 188 00:09:23,585 --> 00:09:24,945 other emerging cancer treatments? 189 00:09:27,385 --> 00:09:28,845 - So, with respect to Theo Bio, 190 00:09:28,905 --> 00:09:31,045 it has been a very long term project 191 00:09:31,195 --> 00:09:35,405 that started more than 20 years ago, uh, where, um, 192 00:09:35,715 --> 00:09:39,765 with my scientific partner, Alexon Baa Frenchman, uh, 193 00:09:39,765 --> 00:09:44,365 who lives in Kmar, France, we started working on, um, 194 00:09:44,695 --> 00:09:47,965 using a hypothesis that tumors might be sensitive 195 00:09:48,345 --> 00:09:53,285 to certain, um, frequencies, radio frequencies, 196 00:09:53,465 --> 00:09:55,925 and to, uh, test these hypothesis. 197 00:09:55,945 --> 00:09:58,525 We examined a large number of patients with cancer 198 00:09:59,225 --> 00:10:03,285 and identified changes in pulse pressure in layman's 199 00:10:03,485 --> 00:10:06,245 language would be change in the intensity of the pulse 200 00:10:06,515 --> 00:10:08,085 that you could measure with your finger, 201 00:10:08,145 --> 00:10:12,725 but better with a detector that measures changes in, 202 00:10:12,945 --> 00:10:14,805 in, in pulse intensity. 203 00:10:15,785 --> 00:10:20,245 And what we found is that, um, uh, looking at a large number 204 00:10:20,245 --> 00:10:22,085 of patient with different type of tumors, 205 00:10:22,425 --> 00:10:26,045 we found some consistent changes in pulse pressure at 206 00:10:26,045 --> 00:10:29,845 certain frequencies in patient that had the same tumor type. 207 00:10:30,265 --> 00:10:34,645 So let's say you had 20 patient with, uh, breast cancer, 208 00:10:35,345 --> 00:10:38,405 uh, some had early stage, some had advanced stage, 209 00:10:38,545 --> 00:10:41,405 we found similar frequencies, um, 210 00:10:41,795 --> 00:10:43,885 eliciting these changes in pulse pressure. 211 00:10:44,145 --> 00:10:47,925 So having, um, identified that within a few years, 212 00:10:48,185 --> 00:10:51,885 we tested the hypothesis that sending these frequencies 213 00:10:51,905 --> 00:10:55,165 to the patient could have, um, therapeutic effects. 214 00:10:55,625 --> 00:10:59,645 So we launched a feasibility study back in 2003, 215 00:11:00,345 --> 00:11:02,885 and, uh, within a few years had evidence 216 00:11:02,885 --> 00:11:05,485 that we could have an impact on cancer. 217 00:11:05,705 --> 00:11:09,085 All these patients had advanced cancer without curative 218 00:11:09,185 --> 00:11:10,245 uh, opportunities. 219 00:11:11,065 --> 00:11:15,725 And in the first, uh, study that was published in 2009, we 220 00:11:16,245 --> 00:11:19,965 reported a complete response, which mean total disappearance 221 00:11:20,025 --> 00:11:24,205 of disease in a patient with breast cancer was metastasis 222 00:11:24,205 --> 00:11:27,725 to the left femur and the right adrenal glands. 223 00:11:27,725 --> 00:11:31,605 So two location that were, uh, clearly seen on, 224 00:11:31,745 --> 00:11:35,125 on imaging studies, more specifically pet ct. 225 00:11:35,465 --> 00:11:37,205 And within just a few months 226 00:11:37,385 --> 00:11:40,045 of only receiving this treatment, uh, 227 00:11:40,045 --> 00:11:42,525 that patient had a total disappearance of the tumor, 228 00:11:42,615 --> 00:11:44,605 which lasted 11 months. 229 00:11:45,065 --> 00:11:48,165 We had another patient was, uh, stage four breast cancer 230 00:11:48,675 --> 00:11:51,125 that also had metastasis to the bones 231 00:11:51,625 --> 00:11:54,285 and to the liver that had a partial response, 232 00:11:54,295 --> 00:11:58,005 which mean a tumor shrinkage, uh, not total disappearance, 233 00:11:58,065 --> 00:12:00,445 but tumor shrinkage that lasted 13 months. 234 00:12:01,515 --> 00:12:06,045 That led us to expand this work into, um, a tumor type 235 00:12:06,145 --> 00:12:10,525 for which there was very few, uh, treatments, if any at 236 00:12:10,525 --> 00:12:13,045 that time, um, advanced liver cancer, 237 00:12:13,355 --> 00:12:15,725 also called hepatocellular carcinoma. 238 00:12:16,305 --> 00:12:19,885 So together with a former colleague of Sloan Kettering 239 00:12:19,885 --> 00:12:23,245 who had moved to, um, Sao Paulo Brazil, 240 00:12:23,345 --> 00:12:27,765 we conducted a study on 40, uh, two patients with, um, 241 00:12:28,405 --> 00:12:29,845 advanced hepatocellular carcinoma 242 00:12:30,185 --> 00:12:33,085 and we're able to demonstrate that using the same approach, 243 00:12:33,375 --> 00:12:36,765 using a portable device that emitted this low 244 00:12:36,785 --> 00:12:38,045 and fairly safe level 245 00:12:38,045 --> 00:12:41,525 of radiofrequency electromagnetic fields three times a day 246 00:12:41,545 --> 00:12:43,285 for one hour, uh, by means 247 00:12:43,285 --> 00:12:46,045 of a spoon placed in the patient's mouth, uh, 248 00:12:46,065 --> 00:12:50,245 we had about 10% of patient that had significant shrinkage 249 00:12:50,245 --> 00:12:53,725 of the tumor, and another 40% of patients, uh, 250 00:12:54,145 --> 00:12:57,365 in the tumor stopped growing for at least six months. 251 00:12:58,065 --> 00:13:02,405 So with this data in mind, we, um, developed a, 252 00:13:02,865 --> 00:13:06,045 uh, more commercial version of the device, which 253 00:13:06,555 --> 00:13:10,125 took into account all the comments we had received from the 254 00:13:10,125 --> 00:13:12,685 physician they wanted, in particular, to be able 255 00:13:12,685 --> 00:13:16,005 to control the number of treatments they wanted to be able 256 00:13:16,025 --> 00:13:19,365 to monitor whether the treatment was delivered or not. 257 00:13:20,025 --> 00:13:23,405 Uh, and they also wanted a device that would be, uh, 258 00:13:24,115 --> 00:13:27,485 very easy to transport so that the patient could, uh, 259 00:13:27,485 --> 00:13:28,605 take the treatment home. 260 00:13:28,785 --> 00:13:33,725 So in 2013, we established a company in Germany with a goal 261 00:13:33,725 --> 00:13:35,485 of developing a device 262 00:13:35,485 --> 00:13:37,365 that would become commercially available. 263 00:13:37,545 --> 00:13:40,605 And in 2018, we received European approval 264 00:13:40,825 --> 00:13:44,965 for this indication, um, in 2019, 265 00:13:45,185 --> 00:13:49,485 the FDA granted breakthrough designation to this device 266 00:13:49,505 --> 00:13:50,965 for the treatment of liver cancer. 267 00:13:51,705 --> 00:13:56,605 And fast forward on December 11th, 2023, 268 00:13:56,705 --> 00:14:00,685 so less than a month ago, um, we received FDA approval 269 00:14:01,185 --> 00:14:03,765 for the treatment of patient with advanced, uh, 270 00:14:03,935 --> 00:14:07,565 liver cancer hepatocellular carcinoma who failed first line 271 00:14:07,565 --> 00:14:08,605 and second line therapy. 272 00:14:08,905 --> 00:14:13,045 So we're very excited to see these very long-term, uh, 273 00:14:13,245 --> 00:14:15,925 projects, uh, based on the discovery 274 00:14:16,025 --> 00:14:19,885 of frequencies in patient with cancer, um, bear fruit, 275 00:14:19,945 --> 00:14:23,325 and now becoming available for patient with liver cancer 276 00:14:23,455 --> 00:14:25,965 where carano will be the first in the world 277 00:14:26,105 --> 00:14:29,605 to offer these treatments, um, with FDA approval. 278 00:14:31,775 --> 00:14:34,955 - Congratulations again on that accomplishment, Dr. Pass. 279 00:14:34,975 --> 00:14:37,055 That's just incredible. 280 00:14:37,315 --> 00:14:38,615 Uh, were there other treatments that you wanted 281 00:14:38,615 --> 00:14:39,695 to mention that you're excited about? 282 00:14:41,385 --> 00:14:43,485 - Yes, I think, you know, the world of, uh, 283 00:14:43,965 --> 00:14:46,285 oncology has seen some very exciting 284 00:14:46,475 --> 00:14:48,005 development in the past decade. 285 00:14:48,485 --> 00:14:52,885 I would say checkpoint inhibitor immunotherapy has, uh, 286 00:14:53,185 --> 00:14:57,685 really offered a, uh, a, a novel option for treatment 287 00:14:57,705 --> 00:14:59,845 for about 15% of patient of cancer. 288 00:15:00,065 --> 00:15:04,085 But when patient have, um, a tumor that responds 289 00:15:04,085 --> 00:15:07,005 to checkpoint inhibitor, it is a therapy 290 00:15:07,235 --> 00:15:10,405 that is very well tolerated, that has some side effects, 291 00:15:10,585 --> 00:15:13,285 but, uh, in the majority of cases well tolerated 292 00:15:13,585 --> 00:15:16,485 and can provide long-term survival in, in, 293 00:15:16,625 --> 00:15:18,325 in these patients that do response. 294 00:15:19,005 --> 00:15:23,245 I think CAR T-cell is another, uh, very exciting development 295 00:15:23,245 --> 00:15:25,405 that is expanding, that has started 296 00:15:25,465 --> 00:15:28,685 for hematologic malignancies, so blood cancer, 297 00:15:29,265 --> 00:15:33,645 but is now moving into, uh, the arena of solid tumor. 298 00:15:33,945 --> 00:15:38,005 And Caros has been at the forefront of offering, uh, such, 299 00:15:38,105 --> 00:15:42,325 uh, clinical trials to patient with, uh, advanced form 300 00:15:42,345 --> 00:15:44,845 of solid tumor that have no other options. 301 00:15:45,225 --> 00:15:48,165 So that has been also a very exciting development. 302 00:15:48,675 --> 00:15:52,485 Theranostic is probably another, um, development 303 00:15:52,515 --> 00:15:54,805 that has recently received FDA approval. 304 00:15:55,345 --> 00:15:58,805 Uh, theranostics is the use of, uh, antibodies or 305 00:15:59,025 --> 00:16:01,525 or tag, if you wish, that will find, uh, 306 00:16:01,575 --> 00:16:05,005 tumor cells throughout the body, both primary tumor 307 00:16:05,145 --> 00:16:09,285 and metastasis, and get stuck to these tumors 308 00:16:09,555 --> 00:16:14,325 with a irradiating components or a local radiation. 309 00:16:14,425 --> 00:16:17,805 So it's, it allows to deliver radiation 310 00:16:18,385 --> 00:16:21,565 to the tumor only with minimal adverse events 311 00:16:21,585 --> 00:16:22,765 to the rest of the body. 312 00:16:23,265 --> 00:16:27,525 And in 2018, the first, um, indication 313 00:16:27,745 --> 00:16:30,885 for neuroendocrine tumor received FDA approval. 314 00:16:31,025 --> 00:16:34,365 And in 2022, uh, another indication 315 00:16:34,585 --> 00:16:37,965 for metastatic prostate cancer received FDA approval. 316 00:16:38,345 --> 00:16:41,165 So I think it's a field where we're gonna see, uh, 317 00:16:41,165 --> 00:16:44,005 additional indication for other tumor types 318 00:16:44,105 --> 00:16:45,845 or earlier stage of the disease. 319 00:16:46,345 --> 00:16:49,365 And, uh, Carmano sees that the leading edge 320 00:16:49,365 --> 00:16:51,285 of developing this novel technology 321 00:16:51,945 --> 00:16:55,525 and, um, um, offering clinical trial to patient 322 00:16:55,635 --> 00:16:57,965 with various form of tumors, uh, 323 00:16:57,995 --> 00:17:00,125 that will benefit from this, uh, 324 00:17:00,285 --> 00:17:02,045 therapeutic, um, innovation. 325 00:17:03,865 --> 00:17:05,065 - Excellent. Thank you so much, doctor. 326 00:17:05,325 --> 00:17:08,265 Lastly, I simply wanted to ask you, what's one goal 327 00:17:08,885 --> 00:17:11,665 in particular that Karmanos has for 2024 328 00:17:11,665 --> 00:17:13,385 that you're looking forward to achieving? 329 00:17:14,955 --> 00:17:17,435 - I would say two goals, growth and expansion. 330 00:17:17,695 --> 00:17:20,595 We are on, we're recruiting new investigators, 331 00:17:20,925 --> 00:17:24,075 we're expanding our, uh, clinical basic 332 00:17:24,175 --> 00:17:25,555 and translational research, 333 00:17:26,095 --> 00:17:29,515 and we want to become the leader in healthcare disparities. 334 00:17:29,975 --> 00:17:33,075 Uh, Dr. Haley Thompson has run a, uh, 335 00:17:33,105 --> 00:17:34,955 fantastic community outreach 336 00:17:34,955 --> 00:17:37,515 and engagement program, uh, in Detroit 337 00:17:37,655 --> 00:17:39,355 and throughout the state of Michigan 338 00:17:39,745 --> 00:17:43,315 with already sh showing already impact on, um, 339 00:17:43,365 --> 00:17:46,475 healthcare disparities that are noted nationwide. 340 00:17:46,855 --> 00:17:49,605 And I think this is one of the key priorities we want 341 00:17:49,665 --> 00:17:51,045 to further expand. 342 00:17:52,555 --> 00:17:54,735 - Dr. Pash, thank you so much for being so generous 343 00:17:54,735 --> 00:17:56,175 with your time and insights today. 344 00:17:56,595 --> 00:17:58,215 We can't wait to share them with our audience, 345 00:17:58,235 --> 00:17:59,815 and we look forward to connecting with you soon. 346 00:18:00,385 --> 00:18:01,455 - Thank you very much, grace. 347 00:18:01,515 --> 00:18:03,015 It was a pleasure speaking with you. 348 00:18:03,015 --> 00:18:05,695 Looking forward to speaking with you in the future. Bye-Bye. 349 00:18:07,805 --> 00:18:10,535 - It's so important for leaders at the top of organizations 350 00:18:10,535 --> 00:18:13,055 to keep learning, stay sharp, grow their networks, 351 00:18:13,445 --> 00:18:15,895 help our audience better do this in a more simplified, 352 00:18:15,895 --> 00:18:17,575 personalized, and meaningful way. 353 00:18:18,135 --> 00:18:20,615 Becker's Healthcare has launched my BHC, 354 00:18:21,045 --> 00:18:22,895 it's your trusted Becker's healthcare experience 355 00:18:22,895 --> 00:18:24,735 and more with content, connections, 356 00:18:24,755 --> 00:18:26,175 events and learning opportunities. 357 00:18:27,085 --> 00:18:28,175 Join the community free 358 00:18:28,175 --> 00:18:32,975 of charge@www.my dot becker's hospital review.com 359 00:18:33,075 --> 00:18:33,895 and we'll see you there.